The estimated Net Worth of Matthew Rabinowitz is at least $299 million dollars as of 8 August 2024. Matthew Rabinowitz owns over 190,000 units of Natera Inc stock worth over $183,348,642 and over the last 9 years he sold NTRA stock worth over $112,856,402. In addition, he makes $2,514,560 as Executive Chairman of the Board et Co-Founder at Natera Inc.
Matthew has made over 60 trades of the Natera Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 190,000 units of NTRA stock worth $1,026,000 on 8 August 2024.
The largest trade he's ever made was selling 732,831 units of Natera Inc stock on 19 June 2016 worth over $8,750,002. On average, Matthew trades about 78,249 units every 38 days since 2015. As of 8 August 2024 he still owns at least 1,480,648 units of Natera Inc stock.
You can see the complete history of Matthew Rabinowitz stock trades at the bottom of the page.
Dr. Matthew Rabinowitz Ph.D. serves as Executive Chairman of the Board, Co-Founder of the Company. Dr. Rabinowitz served as our Chief Executive Officer from 2005 to January 2019, and served as a member of our board of directors since 2005. He served as Chairman of our board of directors from May 2015 to January 2019, at which time he assumed the role of Executive Chairman. Prior to co-founding our company, Dr. Rabinowitz served from 2000 to 2003 as chief executive officer and from 2003 to 2007 as chief technology officer of Rosum Corporation, a location services technology company. Dr. Rabinowitz served as a consulting professor at Stanford University from 2004 to 2012 and as visiting faculty in the Genetics Department of Harvard University from 2018 to 2019. Dr. Rabinowitz has over 100 patents and publications in signal processing, machine learning, bio-informatics, and high-throughput genetic testing. He received the Scott Helt Memorial Award from the Institute of Electrical and Electronics Engineers and has twice received the Technology Pioneer Award from the World Economic Forum. He currently serves as a member of the board of directors or advisory board of a number of technology companies. Dr. Rabinowitz holds a Bachelor of Science degree in Engineering and Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering, from Stanford University. Our board of directors believes that Dr. Rabinowitz is qualified to serve as a director based on his experience as our co-founder and Chief Executive Officer, his service on a private company board, and his experience in the technology industry.
As the Executive Chairman of the Board et Co-Founder of Natera Inc, the total compensation of Matthew Rabinowitz at Natera Inc is $2,514,560. There are 3 executives at Natera Inc getting paid more, with Steven Chapman having the highest compensation of $6,200,910.
Matthew Rabinowitz is 47, he's been the Executive Chairman of the Board et Co-Founder of Natera Inc since 2019. There are 10 older and 6 younger executives at Natera Inc. The oldest executive at Natera Inc is Herman Rosenman, 72, who is the Independent Director.
Matthew's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.
Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy et Roelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Natera Inc executives and other stock owners filed with the SEC include: